By Counterforce Health Team in Lutathera (lutetium Lu-177 dotatate) —

Work With Your Doctor to Get Lutathera Covered by Blue Cross Blue Shield in Michigan: Provider Collaboration Guide

Answer Box: Getting Started

Blue Cross Blue Shield of Michigan requires prior authorization for Lutathera (lutetium Lu-177 dotatate) for neuroendocrine tumors. Your best path: (1) Schedule a focused visit with your oncologist to review BCBSM's specific criteria, (2) gather required documentation including Ga-68 DOTATATE PET results and prior treatment records, and (3) submit a complete prior authorization request through your provider's BCBSM portal. Start this process at least 2-3 weeks before your planned treatment date. If denied, Michigan offers expedited external review through DIFS within 72 hours for urgent cases.

Table of Contents

  1. Set Your Goal: Understanding BCBSM Requirements
  2. Visit Preparation: What to Bring
  3. Building Your Evidence Kit
  4. Medical Necessity Letter Structure
  5. Supporting Your Doctor in Peer-to-Peer Reviews
  6. After Your Visit: Documentation and Follow-Up
  7. Respectful Persistence: When and How to Follow Up
  8. Appeals Process in Michigan
  9. FAQ

Set Your Goal: Understanding BCBSM Requirements

Before your appointment, understand what Blue Cross Blue Shield of Michigan needs to approve Lutathera. According to BCBSM's medical policy, you'll need:

Core Requirements Checklist

  • Confirmed diagnosis: Well-differentiated neuroendocrine tumor with pathology report
  • SSTR-positive status: Ga-68 DOTATATE PET scan showing somatostatin receptor expression
  • Disease characteristics: Ki67 index ≤20%, Karnofsky performance status ≥60
  • Prior treatment: Documentation of progression despite somatostatin analog therapy
  • Prescriber qualification: Request from or consultation with an oncologist
  • Site of care: Treatment at hospital or approved infusion center
Tip: Print this checklist and bring it to your appointment. Your doctor can confirm which items you already have and identify what's missing.

Visit Preparation: What to Bring

Come prepared with a clear timeline of your NET journey. Your oncologist needs specific details to craft a compelling prior authorization request.

Essential Information to Organize

Symptom Timeline

  • When symptoms first appeared
  • How they've progressed or changed
  • Current functional limitations (work, daily activities)

Treatment History

  • All NET-related medications tried (octreotide, lanreotide, everolimus)
  • Dates of treatment, doses, and outcomes
  • Reasons for stopping (progression, side effects, intolerance)
  • Any surgical interventions and results

Current Status

  • Recent imaging results and dates
  • Laboratory values (especially tumor markers)
  • Current symptoms and their impact on quality of life
Note: If you've been treated at multiple facilities, request records in advance. BCBSM reviewers want to see the complete picture.

Building Your Evidence Kit

Your doctor will need comprehensive documentation to support the prior authorization. Help them gather these materials:

Required Clinical Documentation

  • Pathology report confirming neuroendocrine tumor diagnosis
  • Ga-68 DOTATATE PET scan (within 3-6 months) showing SSTR positivity
  • Previous imaging demonstrating disease progression
  • Treatment records from prior somatostatin analog therapy
  • Performance status assessment (Karnofsky scale documentation)

Supporting Guidelines and Literature

Your physician should reference these in the medical necessity letter:

Medical Necessity Letter Structure

A strong letter of medical necessity follows a specific format that addresses BCBSM's criteria point by point. Here's what your doctor should include:

Essential Components

Patient Information Section

  • Full name, date of birth, BCBSM member ID
  • ICD-10 diagnosis codes (e.g., C25.9 for pancreatic NET)
  • Treating physician credentials and contact information

Clinical Rationale

  • Confirmation of well-differentiated, SSTR-positive GEP-NET
  • Reference to FDA-approved indication
  • Evidence of disease progression on prior therapy
  • Explanation why alternatives are unsuitable

Treatment Plan

  • Proposed 4-cycle regimen (7.4 GBq every 8 weeks)
  • Expected clinical benefits
  • Radiation safety compliance statement

Supporting Evidence

  • Attachment list (pathology, imaging, treatment records)
  • Guideline references (NCCN, FDA label)
  • Literature citations if applicable
From our advocates: We've seen providers strengthen their letters by including a specific statement about radiation safety compliance: "Our facility adheres to all federal and state radiation safety regulations, with trained staff and appropriate safety protocols in place." This addresses a common BCBSM concern about administration requirements.

Supporting Your Doctor in Peer-to-Peer Reviews

If BCBSM requests a peer-to-peer review, your oncologist will speak directly with their medical director. You can help by providing key talking points:

Preparation for Your Doctor

Clinical Summary Points

  • Your specific NET type and grade
  • SSTR-positive imaging results and dates
  • Prior treatment timeline with clear progression dates
  • Current functional status and symptoms

Policy Alignment

  • Confirmation that you meet all BCBSM criteria
  • Reference to FDA approval and NCCN guidelines
  • Emphasis on medical necessity and lack of alternatives

Availability Windows Offer to help coordinate scheduling by providing your doctor's preferred call times and ensuring they have all documentation readily available.

After Your Visit: Documentation and Follow-Up

What to Save

  • Copy of the prior authorization request
  • All submitted documentation
  • BCBSM reference numbers and submission dates
  • Contact information for the reviewing department

Portal Messaging Strategy

Use your patient portal to:

  • Confirm receipt of PA submission
  • Request status updates at appropriate intervals
  • Provide additional information if requested

Track all communications in a simple log with dates, contacts, and outcomes.

Respectful Persistence: When and How to Follow Up

Timeline for Follow-Up

  • Week 1: Confirm PA submission and reference number
  • Week 2: Check status if no response received
  • Week 3: Request estimated decision timeline
  • Beyond 3 weeks: Escalate through appropriate channels

Professional Communication

When following up:

  • Reference your case number and submission date
  • Be specific about what information you need
  • Offer to provide additional documentation
  • Maintain a collaborative tone focused on patient care

Appeals Process in Michigan

If BCBSM denies your Lutathera request, Michigan offers robust appeal options through the Department of Insurance and Financial Services (DIFS).

Internal Appeal Process

  • Timeline: 30-60 days from denial
  • Submission: Through BCBSM member portal or written request
  • Documentation: Include all supporting clinical evidence
  • Decision: Typically within 30 days

External Review Through DIFS

If internal appeals fail, Michigan's external review process provides independent medical review:

  • Filing window: 127 days from final internal denial
  • Standard review: Decision within 60 days
  • Expedited review: 72 hours for urgent cases
  • Cost: Free to patients
  • Decision: Binding on BCBSM

Expedited Appeals for Urgent Cases

For situations where treatment delay could harm your health:

  • Requires physician letter stating medical urgency
  • Decision within 72 hours
  • Available through DIFS online form

Counterforce Health specializes in turning insurance denials into successful appeals by analyzing payer policies and crafting evidence-backed responses. Their platform helps patients, clinicians, and specialty pharmacies navigate complex prior authorization requirements and appeals processes for treatments like Lutathera. Learn more about their services.

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required before treatment BCBSM provider portal BCBSM PA Guidelines
SSTR Positivity Ga-68 DOTATATE PET required Nuclear medicine facility FDA Label
Oncologist Consultation Must involve cancer specialist Your medical team BCBSM Policy
Site of Care Hospital/infusion center only Treatment facility BCBSM Medical Policy
Performance Status Karnofsky ≥60 required Clinical assessment Medical Literature

FAQ

How long does BCBSM prior authorization take for Lutathera? Standard review takes 5-7 business days, with expedited reviews completed in 24-48 hours for urgent cases.

What if Lutathera isn't on BCBSM's formulary? Lutathera requires prior authorization regardless of formulary status. The PA process evaluates medical necessity based on clinical criteria.

Can I request an expedited appeal in Michigan? Yes, if your physician certifies that treatment delay would seriously jeopardize your health, you can request expedited external review through DIFS with a 72-hour decision timeline.

What happens if my NET was diagnosed outside Michigan? Out-of-state diagnoses are acceptable as long as all required documentation (pathology, imaging, treatment records) is included in your PA request.

Does step therapy apply to Lutathera? Yes, BCBSM typically requires documentation of progression on somatostatin analog therapy before approving Lutathera.

How much does Lutathera cost without insurance? Lutathera is billed per millicurie using HCPCS code A9513. The total cost varies by facility but is typically substantial, making insurance coverage essential.

Can my family help with the appeals process? Yes, you can authorize family members to communicate with BCBSM on your behalf, and they can assist with gathering documentation and tracking deadlines.

What if I need treatment urgently? Work with your physician to request expedited prior authorization and, if denied, file for expedited external review through Michigan DIFS with appropriate medical documentation.

Sources & Further Reading

Disclaimer: This guide provides educational information about insurance coverage processes and should not be considered medical advice. Always consult with your healthcare providers about treatment decisions and work with your insurance plan directly for coverage determinations. For additional help with insurance appeals in Michigan, contact DIFS at 877-999-6442 or visit their consumer assistance page.

For complex prior authorization challenges, consider working with specialized services like Counterforce Health, which helps transform insurance denials into successful appeals through evidence-based advocacy and payer-specific expertise.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.